Launch week offerEnds in00h00m00s

annual Promonthly Pro

Anmol Baranwal

Assistant Professor

Rush University Medical Center

United States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (17)

Collaborators (8)

Hemant Murthy

associate professor of medicine

Mayo Clinic Research Florida

UNITED STATES

Antoine Saliba

UNITED STATES

Anand Ashwin Patel

Assistant Professor of Medicine

UNITED STATES

Sharad Kumar

Badley Distinguished Professor

University of South Australia

Anna Brown

Adjunct Associate Professor

University of South Australia

Christopher Hahn

University of South Australia

William Hogan

Mayo Clinic Minnesota

UNITED STATES

Hamish Scott

University of South Australia

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Anmol Baranwal

Research Interests

Make your next move.

Explore related searches

Articles (17)

Collaborators (8)

Hemant Murthy

Antoine Saliba

Anand Ashwin Patel

Sharad Kumar

Anna Brown

Christopher Hahn

William Hogan

Hamish Scott

Make your next move.

Anmol Baranwal

Research Interests

Make your next move.

Explore related searches

Articles (17)

Coronary Artery Calcification as a Predictor of Survival in Patients Receiving Post-transplant Cyclophosphamide for GVHD Prophylaxis

Dynamic-EASIX DRI Model: A Novel Tool for Predicting Outcomes After Allogeneic Hematopoietic Cell Transplantation

Single dose antithymocyte globulin effectively reduces GVHD and improves survival in patient undergoing myeloablative matched sibling alloHCT

Factors associated with survival following allogeneic transplantation for myeloid neoplasms harboring TP53 mutations.

Evidence-based risk stratification of myeloid neoplasms harboring TP53 mutations

Validation of the 5th edition of the World Health Organization and International Consensus Classification guidelines for TP53-mutated myeloid neoplasm in an independent international cohort

Outcomes of Post‐Transplant Rh‐GCSF and Decitabine Maintenance Therapy in Patients With High‐Risk Myeloid Neoplasm

Risk of Relapse Post Reduced Intensity Conditioning Allogeneic Stem Cell Transplant in Patients With High‐Risk Myeloid Neoplasms Based on GvHD Prophylaxis: PTCy Vs. TAC/MTX

Comparison of Chimerism Kinetics and Associated Outcomes in Patients Receiving Post-Transplant Cyclophosphamide Versus Methotrexate based GVHD Prophylaxis Following Allogeneic Hematopoietic Cell Transplant

Outcomes of attenuated dose fludarabine and melphalan based conditioning regimen in patients undergoing allogeneic stem cell transplant: a propensity score-matched analysis

Surrogates of Endothelial Injury Predict Survival After Post-transplant Cyclophosphamide

Genetic features and outcomes of allogeneic transplantation in patients with WT1-mutated myeloid neoplasms

Clinicopathologic correlates and prognostic impact of lymphoid aggregates in patients with myelodysplastic syndromes

The impact of cytotoxic therapy on the risk of progression and death in clonal cytopenia(s) of undetermined significance

TP53 mutation variant allele frequency of ≥10% is associated with poor prognosis in therapy-related myeloid neoplasms.

Comparison of Pretransplantation Prediction Models for Nonrelapse Mortality in Patients with Myelofibrosis Undergoing Allogeneic Stem Cell Transplantation

The clinical and molecular spectrum of ETV6 mutated myeloid neoplasms

Collaborators (8)

Hemant Murthy

Antoine Saliba

Anand Ashwin Patel

Sharad Kumar

Anna Brown

Christopher Hahn

William Hogan

Hamish Scott

Make your next move.